PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
News|Articles|July 23, 2013
Zeiss Acquires Xradia
Author(s)Pharmaceutical Technology Editors
Zeiss announced the acquisition of U.S.-based Xradia, Inc.
Advertisement
Zeiss announced that the acquisition of U.S.-based Xradia, Inc. has been completed and Xradia is now operating under the name of Carl Zeiss X-ray Microscopy, Inc. The acquisition further strengthens the position of the ZEISS Microscopy business group, a manufacturer of light, electron, and X-ray microscopes, with solutions for research and routine inspection in materials and life sciences application fields, the company reports in a press statement.
Zeiss says reports the company will leverage its sales force to make the X-ray technology more accessible in a broader range of applications and workflows. Customers will also benefit from direct service capabilities at multiple locations globally.
Advertisement
Related to this article
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Advertisement
Advertisement